Chapter 16

WT1-Associated Protein–Protein Interaction Networks

Ruthrothaselvi Bharathavikru and Alex von Kriegsheim

Abstract

Tumor-suppressor protein Wt1 has been shown to interact with specific proteins that influence its function. These protein interactions have been identified as direct individual interactions but with the potential to exist as a part of a multiprotein complex. In order to obtain the global proteome interaction map of Wt1, an unbiased label-free endogenous immunoprecipitation was performed followed by mass spectrometry to identify protein interactions that are Wt1 centric. This chapter details the different techniques that have been used to identify and characterize Wt1-interacting proteins.

Key words Immunoprecipitation , Proteome , Protein interaction , Mass spectrometry

1 WT1-Associated Proteome

Tumor-suppressor protein Wt1 is a transcription factor that has been shown to have both transcriptional activation and repression properties. Studies have shown that Wt1 interacts with other proteins with functional implications. Wt1-interacting proteins can be broadly classified into three functional categories, (a) transcriptionrelated proteins, (b) cell cycle and apoptosis regulators, (c) splicing pathway components. These have been identified using several biochemical techniques such as yeast two-hybrid analysis, immuno pulldowns, and mass spectrometric analyses and validated by $immunoprecipitation (IP) followed by immunoblots/western$ blotting approaches as well as by performing immunofluorescence to observe colocalization. A brief overview of these different functional categories of interacting proteins is followed by detailed protocols that have been used to identify and understand the significance of Wt1 interactome.

1.1 Functional Categories of Wt1- Interacting Proteins (A) **Transcription-Related Proteins**: Tumor-suppressor protein p53 was one of the first Wt1-interacting proteins to be identified. This was later extended to include p63 and p73 as well. Several important transcription factors including STAT3, ERα, SRY, and

Nicholas Hastie (ed.), *The Wilms' Tumor (WT1) Gene: Methods and Protocols*, Methods in Molecular Biology, vol. 1467, DOI 10.1007/978-1-4939-4023-3_16, © Springer Science+Business Media New York 2016

Pax2 as well as general transcription factors such as TBP and TFIIB have been shown to physically interact with Wt1 (reviewed in ref. [1\)](#page-7-0). Wt1 has also been shown to interact with transcription cofactors both coactivators and corepressors such as CBP, WTIP, and Basp1 to influence the transcriptional response.

- (B) **Cell Cycle Regulators**: Wt1-interacting proteins with an implication towards cell cycle regulation such as p53 were identified initially. However, a few recent studies have identified Wt1 interaction with Htra2, a serine protease $[2]$ with a role in apoptosis as well as interaction with a cell cycle checkpoint regulator MAD2 $\lceil 3 \rceil$. The heat-shock protein hsp70 which has several important regulatory roles including cell cycle is also a well-known Wt1-interacting protein [4].
- (C) **Components of the Splicing Pathway**: Wt1 and its association with splicing factors and hnRNPs have been known for more than a decade. The study with U2AF65 was the outcome of a yeast two-hybrid assay, leading to the identification of a Wt1-interacting protein associated with the splicing machinery $[5]$. The +KTS isoform was seen to have better interaction with U2AF65. Incidentally, U2AF65 is essential for the recruitment of U2 snRNP. Yet another Wt1-interacting protein, WTAP, has also been implicated in alternative splicing events, especially the splice site selection. The Wt1 and RBM4 interaction is yet another study linking Wt1 and alternative splicing wherein minigenes were used to understand the contribution of Wt1 and RBM4 on their splicing (reviewed in ref. [6](#page-7-0)). The contribution of the isoforms as well as the actual mechanism in these processes needs further investigation.
- (D) **Other Interacting Proteins**: Wt1 has also been shown to interact with structural proteins such as actin $[7]$ and also with epigenetic factors such as DNMT1 $[8]$ and the dioxygenase Tet2 $[9]$ recruiting them to their target-binding sites to facilitate epigenetic modifications.

2 Materials

1. **Proteins:**

The protein–protein interaction studies have been mostly performed with overexpression constructs wherein tagged versions of the proteins were transfected and purified from cells with the help of a tag. Thus far, only few interaction and global proteomics experiments have been performed with endogenous Wt1-expressing cell lines. All the centrifugation steps have been performed in a microfuge.

2. **Reagents:**

Agarose resins for tag purifications such as GST (Amersham), hexa-histidine (SIGMA), and anti-FLAG (SIGMA) have been used for enriching the tagged proteins as well as for interaction studies. Agarose-conjugated Wt1 antibody (sc-192) was used for the IP. Protein A/G agarose beads (sc-2003) used routinely for pre-clearing of lysates and control IPs.

- 1. **Gentle Lysis Buffer**: 10 mM Tris–HCl at pH 7.5, 10 mM NaCl, 10 mM EDTA, 0.5 % Triton X-100, 1 mM PMSF, 1× protease inhibitor cocktail, 1 mM DTT, and 10 μg/ml of RNase A.
	- 2. **RIPA Buffer**: 150 mM NaCl, 1 % Triton X-100, 0.5 % sodium deoxycholate, 0.1 % SDS, 50 mM Tris–HCl, pH 8.0 with protease inhibitors (see Notes for further information)
	- 3. **For RNA-binding proteins** (RBPs), the lysis buffer is modified to gentle lysis buffer, gentle lysis buffer: 10 mM Tris–HCl pH 7.5, 10 mM NaCl, 10 mM EDTA, 0.5 % Triton X-100, 1 mM PMSF, 1× protease inhibitor cocktail, 1 mM DTT, and 10 μg/ml of RNase A. NaCl was added to the cleared lysate to a final concentration of 200 mM.
	- 4. **Buffer 1**: 20 mM Tris–HCl (pH 7.9), 20 % glycerol, 1 mM EDTA, 5 mM $MgCl₂$, 0.1% NP-40, 1 mM dithiothreitol (DTT) ,0.2 mM phenylmethylsulfonyl fluoride (PMSF), 0.1 M NaCl (DTT and PMSF added on the day of the experiment).
	- 5. **Buffer 2**: 20 mM Tris–HCl (pH 7.9), 20 % glycerol, 1 mM EDTA, 5 mM $MgCl_2$, 0.1% NP-40, 1 mM DTT, 0.2 mM PMSF, 1 M NaCl (add the DTT and PMSF on the day of the experiment).
	- 6. **Buffer 3**: 20 mM Tris–HCl (pH 7.9), 20 % glycerol, 5 mM $MgCl_2$, 5 mM CaCl₂, 0.1% NP-40, 1 mM DTT, 0.2 mM PMSF, 0.1 M NaCl (add the DTT and PMSF on the day of the experiment).

3 Methods

2.1 Buffer Composition

- 1. Plasmids were transformed into the respective strains using the lithium acetate method followed by analysis for interactions which was tested by growing leu–trp–his– media supplemented with [5](#page-7-0)0 mM 3-amino triazole $\lceil 5 \rceil$. *3.1 Yeast Two Hybrid*
	- 2. The β -galactosidase activity was tested by using filters from leu–trp– plates and liquid assays in leu–trp– media.
	- 3. The activity of β-galactosidase was calculated using the following formula: $1000 \times A420$ / (volume \times time \times protein concentration).

- 7. Beads washed twice with PBS at 2000 rpm for 5 min, 4 °C.
- 8. The immunoprecipitated beads subjected to snap freezing using liquid nitrogen.

The samples were digested with trypsin and then analyzed on a Q-Exactive coupled to an LC with a homemade C18 ReproSil Aq 1.8 μm column as previously described in ref. [10](#page-7-0). Peptides were eluted using a linear gradient from 2 to 32 % acetonitrile over 40 min. Data analysis and label-free quantification were done by using MaxQuant searching against a mouse IPI database. The overall schematic of the label-free proteomic experiment is repre-sented in Fig. [1a.](#page-5-0) *3.5 Mass Spec Acquisition*

 1. GST resin (10 μl packed volume so about 25 μl of resin) is taken per IP reaction. *3.6 In Vitro Protein– Protein*

- 2. Wash the resin three times with **buffer 1** (ten times volume of beads so $100 \mu l$).
- 3. Protein GST and GST-Wt1 (500 ng each) mixed individually with the resin in buffer 1 and left on rotor in cold room for 1½ to 2 h.
- 4. Above samples centrifuged (735 \times g, 4 °C, 5 min). Washed with **buffer 2**, three times, and **buffer 3**, three times (100 μl each).
- 5. Target protein diluted (His-tagged interacting protein X) in **buffer 3** such that there is 500 ng of protein in 5 μl volume. The washed beads from **step 4** mixed with the target protein and IP is performed in **buffer 3** in a total volume of 50 μ l. In cold room, on rotor for 2 h. Samples centrifuged at $735 \times g$, 4 °C, 5 min. Supernatant to be used as unbound protein during western blotting.
- 6. Beads washed with **buffer 1,** four times (100 μl each). Sample eluted from the beads using 30 μl of SDS loading dye. Western to be probed with antibodies against the GST and His tag.
- 1. Cells grown on cover slips, subjected to required treatment. Media aspirated. Washed with PBS $(1\times)$, three times for 2 min each.
- 2. Fixation with 4 % PFA (use 0.2 ml if cells on cover slips in a 24-well plate/50 μl for cells in 16-well chamber slide), 10 min at RT on shaker. PFA removed. Washed with PBS $(1 \times)$, three times for 5 min each.
- 3. Permeabilization with 0.25 % Triton X 100 (use 0.2 ml if cells on cover slips in 24-well plate/50 μl for cells in 16-well chamber slide), 10 min RT on shaker (do not exceed the time). Triton removed, washed with PBS $(1\times)$, three times for 5 min each.
- 4. Blocking with 1 % BSA in 1× PBST, 30 min at RT on shaker (0.2 ml for cover slips/50 μl for 16-well chamber slide). Blocking solution discarded.

Interaction Assay

3.7 Colocalization by Immunofl uorescence

Analysis

Fig. 1 An unbiased global WT1-interacting protein analysis by label-free mass spectrometry. (a) A brief schematic of the different steps involved in identifying Wt1-interacting proteins by label-free mass spectrometric approach. (b) A pie chart representation of the different gene ontology categories of Wt1-interacting proteome. The percentage in each category is also represented

- 5. Primary antibody to be added (if two different host antibodies are to be used, a mix of the two antibodies can also be used). 0.2 ml for cover slips/50 μl for 16-well chamber slide. Incubate at RT for 1 h. Aspirate antibody. Wash with $1 \times PBS$ (three times for 5 min each).
- 6. Secondary antibody or a mix added, 0.2 ml for cover slips/50 μl for 16-well chamber slide. Incubated at RT for 1 h wrapped in foil. Antibody aspirated. Washed with $1 \times PBS$ (three times for 5 min each), wrapped in foil.
- 7. If using chamber slide, wells and the protective seal removed. A drop of Vectashield H1200 added, cover slip placed on top. If using cover slips, on a glass slide, a drop of Vectashield H1200 added, the cover slip inverted on to the drop such that the cells are on the bottom side. Edges can be sealed with enamel for later visualization.

Antibody solutions are made in 1 % BSA in 1× PBST.

The interactome analysis utilizes a series of different biochemical techniques to identify and characterize specific interactions. However, recent advances have allowed visualization of molecular interactions, thus providing spatial and temporal resolution to the protein interaction studies in the context of cell biology. Protein– protein interactions can now be visualized in living cells with the help of fluorescence-associated techniques such as FRET and FCS. FRET refers to the fluorescence/Förster resonance energy transfer which employs the differences in the excitation and emission energy of two fluorophores tagged to proteins as explained in ref. [11.](#page-7-0) FCS is fluorescence correlation spectroscopy which also relies on fluorophore-tagged proteins and their hydrodynamic diameter which represents changes based on interaction between the proteins [12]. These most often require additional cloning strategies to introduce the tagged version of the protein; however these techniques facilitate cellular biochemical interactions to be visualized in real time. Proximity ligation assays are yet another way of visualizing the dynamics of protein–protein interaction [[13](#page-7-0)]. *3.8 Discussion*

Global protein–protein interactions can be depicted as interaction networks with the help of databases such as STRING. Alternatively, interaction data can also be analyzed for an over-representation of any particular category of proteins by using the gene ontology tools available online. An example of this is represented in Fig. [1b,](#page-5-0) where Wt1-interacting proteins identified in the epicardial cell line, enriched over a threshold of 2 in comparison to the control, were selected and submitted to the Panther database for analysis of distinct functional categories. This depicts an enrichment for Wt1 interacting proteins in the binding category, structural proteins, and catalytic activity. *3.9 Protein Interaction Networks*

4 Notes

- 1. Use agarose-conjugated antibodies wherever possible: If not antibodies need to be bound to the agarose slurry. (Beads equilibrated in IP buffer by washes at $326 \times g$ 3 min, twice, add antibody at required concentration in 1 ml of IP buffer, end-to-end rotor, 4 °C for 1 h, spin $326 \times g/3$ min, remove supernatant, use these beads as the conjugated antibody for the IP.)
- 2. Overexpression strategies work well when matched with a good empty vector-transfected control.
- 3. Endogenous protein IPs are best since it does not perturb any interactions based on changes in transfection and/or expression efficiency. However, this approach requires additional controls so as to improve the efficiency of identifying true interactions.
- 4. Incorporation of DNase or RNase along with the lysis buffer and the IP buffer also facilitates the exclusion of nonspecific interactions.
- 5. PIERCE staining kit (24612) alternatively can also use the following kit (24600). Make all solutions fresh, use freshly autoclaved water (unopened before), wear gloves at all times, handle gel only with forceps if needed, and use new plates for the processing if possible.

References

- 1. Toska E, Roberts SG (2014) Mechanisms of transcriptional regulation by WT1 (Wilms' tumour 1). Biochem J 461(1):15–32
- 2. Hartkamp J, Carpenter B, Roberts SG (2010) The Wilms' tumor suppressor protein WT1 is processed by the serine protease HtrA2/Omi. Mol Cell 37(2):159–171
- 3. Shandilya J, Toska E, Richard DJ et al (2014) WT1 interacts with MAD2 and regulates mitotic checkpoint function. Nat Commun 5:4903
- 4. Maheswaran S, Englert C, Zheng G et al (1998) Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 requires association with the inducible chaperone Hsp70. Genes Dev 12(8):1108–1120
- 5. Davies RC, Calvio C, Bratt E et al (1998) WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. Genes Dev 12(20):3217–3225
- 6. Morrison AA, Viney RL, Ladomery MR (2008) The post-transcriptional roles of WT1, a multifunctional zinc-finger protein. Biochim Biophys Acta 1785(1):55–62
- 7. Dudnakova T, Spraggon L, Slight J et al (2010) Actin: a novel interaction partner of WT1 influencing its cell dynamic properties. Oncogene 29(7):1085–1092
- 8. Xu B, Zeng DQ, Wu Y et al (2011) Tumor suppressor menin represses paired box gene 2 expression via Wilms' tumor suppressor protein- polycomb group complex. J Biol Chem 286(16):13937–13944
- 9. Wang Y, Xiao M, Chen X et al (2015) WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol Cell 57(4):662–673
- 10. Turriziani B, Garcia-Munoz A, Pilkington R et al (2014) On-beads digestion in conjunction with data-dependent mass spectrometry: a shortcut to quantitative and dynamic interaction proteomics. Biology (Basel) 3(2):320– 332. doi: [10.3390/biology3020320](http://dx.doi.org/10.3390/biology3020320)
- 11. Truong K, Ikura M (2001) The use of FRET imaging microscopy to detect protein-protein interactions and protein conformational changes in vivo. Curr Opin Struct Biol 11(5):573–578
- 12. Macháň R, Wohland T (2014) Recent applications of fluorescence correlation spectroscopy in live systems. FEBS Lett 588(19):3571–3584
- 13. Söderberg O, Leuchowius KJ, Gullberg M et al (2008) Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods 45(3): 227–232